Literature DB >> 16225511

Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.

Paolo Gontero1, Luca Marini, Bruno Frea.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16225511     DOI： 10.1111/j.1464-410X.2005.05739.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  4 in total

1.  Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.

Authors:  Lijun Mao; Chunhua Yang; Liantao Li; Lanzhou Nai; Li Fan; Junqi Wang; Wang Li; Rumin Wen; Jiacun Chen; Junnian Zheng
Journal:  Tumour Biol       Date:  2014-03-07

Review 2.  Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

Authors:  Kyla N Velaer; Ryan L Steinberg; Lewis J Thomas; Michael A O'Donnell; Kenneth G Nepple
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

Review 3.  Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.

Authors:  Chuanjun Zhuo; Xubin Li; Hongqing Zhuang; Shunli Tian; Hailong Cui; Ronghuan Jiang; Chuanxin Liu; Ran Tao; Xiaodong Lin
Journal:  Oncotarget       Date:  2016-12-13

4.  Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.

Authors:  Niv Milbar; Max Kates; Meera R Chappidi; Filippo Pederzoli; Takahiro Yoshida; Alexander Sankin; Phillip M Pierorazio; Mark P Schoenberg; Trinity J Bivalacqua
Journal:  Bladder Cancer       Date:  2017-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.